Warnes K E, McMillen I C, Robinson J S, Coulter C L
Department of Physiology, University of Adelaide, Adelaide, South Australia 5000, Australia.
Biol Reprod. 2004 Aug;71(2):620-8. doi: 10.1095/biolreprod.103.025197. Epub 2004 Apr 7.
It is not clear if an increase in intra-adrenal cortisol is required to mediate the actions of adrenocorticotropic hormone (ACTH) on adrenal growth and steroidogenesis during the prepartum stimulation of the fetal pituitary-adrenal axis. We infused metyrapone, a competitive inhibitor of cortisol biosynthesis, into fetal sheep between 125 and 140 days of gestation (term = 147 +/- 3 days) and measured fetal plasma cortisol, 11-desoxycortisol, and ACTH; pituitary pro-opiomelanocortin mRNA and adrenal expression of ACTH receptor (melanocortin type 2 receptor), steroidogenic acute regulatory protein (StAR), 11beta-hydroxysteroid dehydrogenase type 2 (11betaHSD2), cytochrome P450 cholesterol side-chain cleavage (CYP11A1), cytochrome P450 17-hydroxylase (CYP17), 3beta-hydroxysteroid dehydrogenase, and cytochrome P450 21-hydroxylase mRNA; and StAR protein in the fetal adrenal gland. Plasma ACTH and 11-desoxycortisol concentrations were higher (P < 0.05), whereas plasma cortisol concentrations were not significantly different in metyrapone- compared with vehicle-infused fetuses. The ratio of plasma cortisol to ACTH concentrations was higher (P < 0.0001) between 136 and 140 days than between 120 and 135 days of gestation in both metyrapone- and vehicle-infused fetuses. The combined adrenal weight and adrenocortical thickness were greater (P < 0.001), and cell density was lower (P < 0.01), in the zona fasciculata of adrenals from the metyrapone-infused group. Adrenal StAR mRNA expression was lower (P < 0.05), whereas the levels of mature StAR protein (30 kDa) were higher (P < 0.05), in the metyrapone-infused fetuses. In addition, adrenal mRNA expression of 11betaHSD2, CYP11A1, and CYP17 were higher (P < 0.05) in the metyrapone-infused fetuses. Thus, metyrapone administration may represent a unique model that allows the investigation of dissociation of the relative actions of ACTH and cortisol on fetal adrenal steroidogenesis and growth during late gestation.
在产前刺激胎儿垂体 - 肾上腺轴期间,促肾上腺皮质激素(ACTH)对肾上腺生长和类固醇生成的作用是否需要肾上腺内皮质醇增加尚不清楚。我们在妊娠125至140天(足月 = 147±3天)之间给胎羊输注美替拉酮(一种皮质醇生物合成的竞争性抑制剂),并测量胎儿血浆皮质醇、11 - 脱氧皮质醇和ACTH;垂体阿黑皮素原mRNA以及肾上腺促肾上腺皮质激素受体(黑皮质素2型受体)、类固醇生成急性调节蛋白(StAR)、11β - 羟基类固醇脱氢酶2型(11βHSD2)、细胞色素P450胆固醇侧链裂解酶(CYP11A1)、细胞色素P450 17 - 羟化酶(CYP17)、3β - 羟基类固醇脱氢酶和细胞色素P450 21 - 羟化酶mRNA的表达;以及胎儿肾上腺中的StAR蛋白。与输注溶媒的胎儿相比,美替拉酮处理的胎儿血浆ACTH和11 - 脱氧皮质醇浓度较高(P < 0.05),而血浆皮质醇浓度无显著差异。在美替拉酮处理组和输注溶媒组的胎儿中,妊娠136至140天期间血浆皮质醇与ACTH浓度之比高于妊娠120至135天期间(P < 0.0001)。美替拉酮处理组肾上腺束状带的肾上腺联合重量和肾上腺皮质厚度更大(P < 0.001),细胞密度更低(P < 0.01)。美替拉酮处理的胎儿肾上腺StAR mRNA表达较低(P < 0.05),而成熟StAR蛋白(30 kDa)水平较高(P < 0.05)。此外,美替拉酮处理的胎儿肾上腺11βHSD2、CYP11A1和CYP17的mRNA表达较高(P < 0.05)。因此,给予美替拉酮可能代表一种独特的模型,可用于研究妊娠晚期ACTH和皮质醇对胎儿肾上腺类固醇生成和生长的相对作用的解离。